Effect of Combined Anti-Pd-1 and Temozolomide Therapy in Glioblastoma

OncoImmunology - United States
doi 10.1080/2162402x.2018.1525243
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Temozolomide Nanoparticles for Targeted Glioblastoma Therapy

ACS Applied Materials & Interfaces
MedicineMaterials ScienceNanotechnologyNanoscience
2015English

SCLE and Dermatomyositis in Anti‐PD‐1 Therapy

British Journal of Dermatology
DermatologyMedicine
2019English

Crosslink Between Temozolomide and PD-L1 Immune-Checkpoint Inhibition in Glioblastoma Multiforme

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Tumoral and Immune Heterogeneity in an Anti-Pd-1 Responsive Glioblastoma: A Case Study

Cold Spring Harbor molecular case studies
BiochemistryMolecular MedicineGenetics
2020English

PD-L1 Expression and Combined Status of PD-L1/PD-1–Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients

Journal of Pathology and Translational Medicine
Forensic MedicinePathologyHistology
2017English

Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy

Clinical Cancer Research
Cancer ResearchOncology
2017English

Robust Antitumor Effects of Combined Anti-Cd4-Depleting Antibody and Anti-Pd-1/Pd-L1 Immune Checkpoint Antibody Treatment in Mice

Cancer immunology research
Cancer ResearchImmunology
2015English

Expression of LAG-3 and Efficacy of Combination Treatment With Anti-Lag-3 and Anti-Pd-1 Monoclonal Antibodies in Glioblastoma

International Journal of Cancer
Cancer ResearchOncology
2018English

Rationale of Combination of Anti-Pd-1/Pd-L1 Antibody Therapy and Radiotherapy for Cancer Treatment

International Journal of Clinical Oncology
MedicineSurgeryOncologyHematology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy